Laurus Labs Limited
F&O₹2,060.10▲ +41.60 (+2.06%)
LAURUSLABS·NSE·Healthcare
Market Cap
111250.29 Cr
PE Ratio
125.08
Volume
16,06,316
Day High - Low
2086.00 - 2028.70
52W High-Low
2086.00 - 870.45
₹2,060.10▲ +41.60 (+2.06%)
Market Cap111250.29 Cr
PE Ratio125.08
Volume16,06,316
Day High - Low2086.00 - 2028.70
52W High-Low2086.00 - 870.45
Laurus Labs Limited (LAURUSLABS): company summary
The company's business is improving, with annual revenue rising 22.7% and net profit surging 148.4% year-on-year.
Laurus Labs Limited (LAURUSLABS) is a large-cap Healthcare company valued at ₹1.11 lakh crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Laurus Labs Limited last traded at ₹2,060.1, up 2.06% on the day.
- Recent developments
- 2026-07-27: Laurus Labs reported a 126% year-on-year jump in Q1 FY27 net profit to ₹368 crore, with revenue up 29% to ₹2,026 crore, driven by strong CDMO commercial deliveries. 2026-08-13: Laurus Labs was added to the MSCI Standard Index as part of the MSCI India rejig. 2026-09-21: Laurus Labs hit a new 52-week high as pharma stocks surged.
- Financial performance
- The company's business is improving, with annual revenue rising 22.7% and net profit surging 148.4% year-on-year. The latest quarter saw revenue grow 29.1% and net profit jump 123.5% compared to the same quarter a year earlier, driven by strong CDMO performance. Net profit margin expanded 6.6 percentage points to 13.1%, while return on equity and return on capital employed remained stable at 16.8% and 17.6%, respectively.
- Valuation multiples
- The stock trades at 125.1 times earnings, a premium to the Healthcare median of 32.0, 19.74 times book value. It yields 0.1%.
- Things to watch
- The stock is 1.2% below its 52-week high, and promoter shares pledged account for 2.69% of promoter holding. Domestic institutional holding fell 0.23 percentage points in the quarter, while the 5-year profit CAGR turned negative at -2.0% per year.
- Where it stands
- Laurus Labs has delivered strong growth in both revenue and net profit, with the latest quarter showing a sharp rise in earnings. The company's inclusion in the MSCI Standard Index highlights its growing importance. However, the stock remains slightly below its recent high, and the negative 5-year profit CAGR suggests challenges in sustaining growth over the longer term.
Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.1/10
Weak
Fair Value
Sign in to see
ROE
16.77%
Strong
P/E
125.08x
Expensive
Debt / Equity
0.45
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
NIFTY 200NIFTY 500NIFTY MIDCAP 150
Day₹2029
₹2086
52W₹870.45
₹2086
DocStoX take
Supported by risk (8.7) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 8.7, but that is offset by valuation at 0.0 and growth at 1.8. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence5.1
/10
Weak
Quality
Solid
ROE 16.8%
Valuation
Expensive
P/E 125.1×
Growth
Flat
Revenue +7.2% 5Y CAGR
Risk
Low risk
D/E 0.45
Momentum
Strong
98% of 52-week range
At a glance
Market Cap
₹1.11L Cr
52W High / Low
₹2086 / ₹870
Dividend Yield
0.10%
Promoter Holding
27.47%
EPS (TTM)
₹16.47
Book Value
₹98.18
Key highlights
- Profitable in all of the last 5 years
- Profit shrinking 2% a year
- Valuation is weak (0.0/10)
1 Positive4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Laurus Labs Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Laurus Labs Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises LimitedMax Healthcare Institute Limited
Compare Laurus Labs Limited with peers
Laurus Labs Limited vs Sun Pharmaceutical Industries LimitedLaurus Labs Limited vs Divi's Laboratories LimitedLaurus Labs Limited vs Torrent Pharmaceuticals LimitedLaurus Labs Limited vs Apollo Hospitals Enterprise LimitedLaurus Labs Limited vs Zydus Lifesciences LimitedLaurus Labs Limited vs Cipla Limited
Related tools & concepts
Value Laurus Labs Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing